Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/DHX36_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DHX36_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DHX36_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/DHX36_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DHX36_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/DHX36_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/DHX36_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DHX36_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190236910 | Prostate | BPH | negative regulation of RNA catabolic process | 24/3107 | 75/18723 | 7.53e-04 | 4.98e-03 | 24 |
GO:00002888 | Prostate | BPH | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 19/3107 | 56/18723 | 1.19e-03 | 7.31e-03 | 19 |
GO:00609992 | Prostate | BPH | positive regulation of dendritic spine development | 15/3107 | 42/18723 | 2.14e-03 | 1.19e-02 | 15 |
GO:00323924 | Prostate | BPH | DNA geometric change | 26/3107 | 90/18723 | 2.46e-03 | 1.33e-02 | 26 |
GO:0035051 | Prostate | BPH | cardiocyte differentiation | 40/3107 | 156/18723 | 2.58e-03 | 1.38e-02 | 40 |
GO:00611583 | Prostate | BPH | 3'-UTR-mediated mRNA destabilization | 8/3107 | 17/18723 | 3.36e-03 | 1.73e-02 | 8 |
GO:00314402 | Prostate | BPH | regulation of mRNA 3'-end processing | 11/3107 | 28/18723 | 3.51e-03 | 1.79e-02 | 11 |
GO:00506853 | Prostate | BPH | positive regulation of mRNA processing | 12/3107 | 32/18723 | 3.66e-03 | 1.85e-02 | 12 |
GO:00325082 | Prostate | BPH | DNA duplex unwinding | 24/3107 | 84/18723 | 4.13e-03 | 2.04e-02 | 24 |
GO:0048814 | Prostate | BPH | regulation of dendrite morphogenesis | 20/3107 | 67/18723 | 4.93e-03 | 2.33e-02 | 20 |
GO:00346443 | Prostate | BPH | cellular response to UV | 25/3107 | 90/18723 | 5.18e-03 | 2.43e-02 | 25 |
GO:00094113 | Prostate | BPH | response to UV | 37/3107 | 149/18723 | 6.40e-03 | 2.91e-02 | 37 |
GO:00434897 | Prostate | BPH | RNA stabilization | 19/3107 | 65/18723 | 7.73e-03 | 3.39e-02 | 19 |
GO:20007652 | Prostate | BPH | regulation of cytoplasmic translation | 7/3107 | 16/18723 | 9.80e-03 | 4.13e-02 | 7 |
GO:0061003 | Prostate | BPH | positive regulation of dendritic spine morphogenesis | 8/3107 | 20/18723 | 1.09e-02 | 4.50e-02 | 8 |
GO:00508072 | Prostate | BPH | regulation of synapse organization | 48/3107 | 211/18723 | 1.23e-02 | 4.94e-02 | 48 |
GO:000218119 | Prostate | Tumor | cytoplasmic translation | 115/3246 | 148/18723 | 1.36e-58 | 8.43e-55 | 115 |
GO:000641719 | Prostate | Tumor | regulation of translation | 161/3246 | 468/18723 | 1.55e-19 | 8.74e-17 | 161 |
GO:190331117 | Prostate | Tumor | regulation of mRNA metabolic process | 111/3246 | 288/18723 | 6.66e-18 | 2.30e-15 | 111 |
GO:005068416 | Prostate | Tumor | regulation of mRNA processing | 64/3246 | 137/18723 | 1.55e-15 | 2.75e-13 | 64 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DHX36 | SNV | Missense_Mutation | novel | c.2971N>A | p.Glu991Lys | p.E991K | Q9H2U1 | protein_coding | deleterious(0.02) | benign(0.013) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DHX36 | SNV | Missense_Mutation | | c.319N>A | p.Asp107Asn | p.D107N | Q9H2U1 | protein_coding | tolerated(0.31) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DHX36 | SNV | Missense_Mutation | rs151135113 | c.1070N>A | p.Arg357Gln | p.R357Q | Q9H2U1 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DHX36 | SNV | Missense_Mutation | novel | c.2400G>C | p.Gln800His | p.Q800H | Q9H2U1 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-B6-A402-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PD |
DHX36 | SNV | Missense_Mutation | novel | c.140N>A | p.Arg47Gln | p.R47Q | Q9H2U1 | protein_coding | tolerated(0.59) | possibly_damaging(0.885) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DHX36 | SNV | Missense_Mutation | novel | c.875N>T | p.Tyr292Phe | p.Y292F | Q9H2U1 | protein_coding | tolerated(0.12) | probably_damaging(0.979) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DHX36 | insertion | Nonsense_Mutation | novel | c.1464_1465insTAATTATTTATTTATTAATTTATTTTTGAAAC | p.Gly489Ter | p.G489* | Q9H2U1 | protein_coding | | | TCGA-A8-A07Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Exemestane | SD |
DHX36 | SNV | Missense_Mutation | novel | c.418N>T | p.Leu140Phe | p.L140F | Q9H2U1 | protein_coding | tolerated(0.73) | benign(0) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
DHX36 | SNV | Missense_Mutation | rs747063807 | c.1949N>A | p.Gly650Glu | p.G650E | Q9H2U1 | protein_coding | tolerated(0.71) | benign(0.007) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
DHX36 | SNV | Missense_Mutation | novel | c.1003G>A | p.Glu335Lys | p.E335K | Q9H2U1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A8QM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |